Attenuated Vaccines Market
Market Insights on Attenuated Vaccines covering sales outlook, demand forecast & up-to-date key trends
Attenuated Vaccines Market by Vaccines, Indication, Route of Administration, Age Group, End User & Region - Forecast 2022 - 2032
Attenuated Vaccines Market Outlook (2022-2032)
[307 Pages Report] The attenuated vaccines market is anticipated to reflect a 6.8% forecast CAGR during the period of 2022-2032. As of 2021, the market was valued at US$ 4,170.2 Million and is likely to record a Y-o-Y growth rate of 6.7% to reach US$ 4,451.7 Million in 2022. By the end of the forthcoming decade, a market valuation of US$ 9,305.8 Million is expected for the industry.
“Many government organizations undertaking initiatives to focus on immunization, is one of the major factors that is anticipated to propel the industry growth over the forecast period.”
Diseases including Tuberculosis, yellow fever, retroviral, measles, polio, and other illnesses are all prevented by live attenuated vaccinations, which in turn is expected to accelerate the market growth.
|
Attributes |
Details |
|
Attenuated Vaccines Market CAGR (2022 – 2032) |
6.8% |
|
Attenuated Vaccines Market (2022) |
US$ 4,451.7 Million |
|
Attenuated Vaccines Market (2032) |
US$ 9,305.8 Million |
Let us know your requirement to get
100% FREE customization
Prominent Drivers of Attenuated Vaccines Market
Increasing Incidences of Infectious Diseases Globally to fuel the market growth
The increase in the number of people suffering from infectious diseases across the globe acts as one of the major factors driving the growth of live attenuated vaccines market. In addition, the advent of re-emerging diseases due to overuse of antibiotics, etc. is another factor that is boosting the market growth during the forecast period.
Diseases including Tuberculosis, yellow fever, retroviral, measles, polio, and other illnesses are all prevented by live attenuated vaccinations, which in turn is expected to accelerate the market growth. The increase in the prevalence of fungal diseases globally is escalating the growth of tropical infection globally, which in turn is anticipated to augment the growth of live attenuated vaccines market. Furthermore, rise in demand for novel treatment extends profitable opportunities to the market players during the analysis period.
Government Initiatives to Propel Market Demand
Government initiatives in many nations have resulted in a considerable reduction in the number of cases of polio across the globe. A hike in funding by government to and steps taken to make vaccination compulsory for children.
Additionally, many government organizations undertaking initiatives to focus on immunization is also boosting the market growth. Further, an increase in demand for the program aiming to prevent the spread of transmission and, also to alleviate the suffering accelerate the market growth over the analysis period.
Moreover, rise in awareness, increase in population, funds by public and private organizations, advancements in the healthcare sector, and technological advancements, coupled with the rise in the number of clinical trials conducted by many pharmaceuticals industries positively affect the live attenuated vaccines market.
Key Challenges and Restraints affecting the Attenuated Vaccines Market Growth
Limited Operating Revenue for R&D
Limited operating revenue for research and development of novel drugs is one of the major factors that is expected to impede the growth of the Attenuated Vaccines Market during the forecast period. Moreover, the high cost associated with the development is another factor expected to restrain the market growth.
Low Healthcare Budget & Lack of Awareness
Low healthcare budget especially in developing regions, as well as the lack of awareness regarding the Attenuated Vaccines among the people, are some major factors that are projected to challenge the live attenuated vaccines market during the forecast period, which in turn will hamper the market growth.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystKey Trends for Attenuated Vaccines Market
Adoption of Live Attenuated Vaccines for Vaccines Preparation
Live attenuated vaccines are prepared by weakening the bacterial or viral strains using stable mutations. This technology does not kill the microorganism. It removes the disease-causing ability of the microorganism. The live attenuated vaccines elicits the immune system in a vaccinated individual. Live attenuated vaccines are used to prevent diseases such as tuberculosis, yellow fever, retroviral, measles, polio, and others. Initiatives by governments of various countries has significantly decreased the number of polio cases across the world.
According to the World Health Organization (WHO), since 1988, polio cases have decreased by over 99%. In 2016, only 37 cases were reported as compared to 350,000 in 1988. Over 16 million people have been saved from paralysis attack due to polio. Failure of completely eradicate polio is likely to result in more than 200,000 new cases within 10 years.
Live attenuation technology is most widely used for vaccines preparation. This factor drives the global live attenuated vaccines market. Properties of live attenuated vaccines such as oral administration, low cost of production, prevention by pathogen, long-lasting, and high effectiveness drive the market. Tuberculosis is one of the top ten causes of death globally.
In 2015, tuberculosis accounted for 1.8 million deaths and 10.4 million people were living with the disease. Over 95% deaths due to tuberculosis were in middle- or low-income countries. In 2015, an estimated 170,000 children died and 1 million children were ill with tuberculosis. Regulatory hurdles, genetic stability, and environmental risks are likely to restrain the live attenuated vaccines market.
Comparative Analysis of the Adjacent Attenuated Vaccines Market
Attenuated Vaccines Market:
|
Attributes |
Attenuated Vaccines Market |
|
CAGR (2022 - 2032) |
6.8% |
|
Market Value (2032) |
US$ 9,305.8 Million |
|
Growth Factor |
Adoption of live attenuated vaccines for vaccines preparation is expected to boost the market’s growth. |
|
Opportunity |
Rise in demand for novel treatment extends profitable opportunities to the market players during the analysis period. |
|
Key Trends |
A number of government organizations undertaking initiatives to focus on immunization, which is also boosting the market’s growth. |
Preventive Vaccines Market:
|
Attributes |
Preventive Vaccines Market |
|
CAGR (2022 - 2032) |
6.1% |
|
Market Value (2032) |
US$ 27.7 Billion |
|
Growth Factor |
The increasing prevalence of infectious diseases is expected to fuel the market’s growth. |
|
Opportunity |
Innovative technology in vaccines development is a major factor expected to create lucrative opportunities for the market’s growth. |
|
Key Trends |
Increased funding from government and international organizations is expected to fuel the market’s growth. |
Therapeutics Vaccines Market:
|
Attributes |
Therapeutics Vaccines Market |
|
CAGR (2022 - 2032) |
5.3% |
|
Market Value (2032) |
US$ 5.5 Billion |
|
Growth Factor |
Increasing cases of chronic diseases and need for effective treatment is acting as key driver for this market. |
|
Opportunity |
The overwhelming use of therapeutic vaccines in the healthcare sector are expected bring immense growth opportunities. |
|
Key Trends |
The increasing incidences of numerous diseases and the growing need to diagnose them at an early stage have led to tremendous advancements in the therapeutic vaccines market. |
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Category Wise Analysis for Attenuated Vaccines Market
By Vaccines Type, which Attenuated Vaccines will witness Maximum Uptake?
Monovalent Attenuated Vaccines to register Highest Uptake
According to Future Market Insights, demand for monovalent attenuated vaccines is expected to emerge dominant. The segment is poised to accrue 72.1% of total market revenue, expected to reach a valuation of US$ 3,006.7 Million.
Monovalent vaccines generally provide immunity against a single antigen or micro-organism. Given several instances wherein administering multivalent vaccines have paved way for mutation of existing microbe strains, reliance on monovalent vaccines is expected to rise in the future.
Which Segment is likely to dominate the Market by Indication?
Chickenpox to remain dominant, Rotavirus Vaccines to gain major traction
Based on indication, attenuated vaccines for treating chickenpox will comprise bulk of the global market share, valued at 38.1%. As per FMI’s report, the segment is expected to be valued at US$ 1,588.8 Million by the end of the 2022-2032 forecast period.
Simultaneously, prospects for rotavirus treatment are likely to aggrandize, with an expected forecast CAGR of 10% until 2032. Accounting for 11.2% of the global market for attenuated vaccines, the segment is poised to reach a valuation of US$ 467.1 Million.
Region Wise Analysis for Attenuated Vaccines Market
Will North America emerge as an Attractive Attenuated Vaccines Market?
Extensive R&D and Vaccination Drives to eradicate COVID-19 have Heightened Prospects in the Region
North America is expected to provide significant expansion prospects for the attenuated vaccines market. Securing a market share of 38.7%, the region is slated to flourish at a CAGR of 5.5% during the 2022-2032 forecast period. By the end of the aforementioned decade, a market value of US$ 1,613.9 Million is anticipated for North America. Extensive R&D to discover new breakthroughs for key infectious diseases is driving market growth.
Besides initiatives taken by the government for vaccination against diseases like influenza, the market has immensely benefitted due to extensive drug discovery and vaccines research undertaken to counter the menace of COVID-19. With support from leading global players including Pfizer, Moderna and Janssen/J&J, the government has successfully deployed and vaccinated 221 Million as of May 2022, or 67% of the local population.
How Opportunistic will the Market for Attenuated Vaccines be across Asia Pacific?
India to be an Emerging Ground for Administering Attenuated Vaccines for Major Infectious Diseases
Collectively, the Asia Pacific region is expected to be highly lucrative, comprising of East Asia, South Asia and Oceania respectively. While East Asia is likely to account for 9.1% of total market value, South Asia is anticipated to be the highest revenue grosser, accounting for 12.4% of the total market, and expanding at a 10.7% value CAGR until 2032.
India is anticipated to be the chief growth driver for the market for attenuated vaccines across South Asia. In 2014, the Indian Government initiated Mission Indradhanush, an extensive immunization program covering nearly 27 Million new-born babies annually. The Programme introduced new vaccines, including the Pneumococcal Conjugate Vaccines (PCV) and Rotavirus Vaccines (RVV).
India’s commitment to improving access to vaccines has been a particularly important intervention in reducing child mortality and morbidity, and immunization remains a priority amongst decision-makers at the highest levels of government. Regular and effective immunization may be able to eradicate many diseases that plague India.
Who are the Key Competitors in the Attenuated Vaccines Market?
Merck & Co., Inc., GlaxoSmithKline plc. Pfizer Inc., Sanofi, Astellas Pharma, CSL Limited, Serum Institute of India Pvt. Ltd., BioDiem, AstraZeneca, Emergent BioSolutions Inc., Vivaldi Biosciences Inc., and Excavators, among others are the top companies in the global attenuated vaccines market.
With a sizable attenuated vaccines market share, these main firms are concentrating on growing their consumer base into new countries. These businesses are making use of strategic collaboration initiatives to grow their market share and profits.
Mid-size and smaller businesses, on the other hand, are expanding their market presence by gaining new contracts and entering new markets, thanks to technical developments and product innovations.
Recent Developments
- In May 2022, Codagenix Inc., a clinical-stage synthetic biology company with a rational vaccines design platform aimed at infectious diseases and cancer, in collaboration with the Serum Institute of India Pvt. Ltd., announced that the first patient has been dosed in a U.K.-based Phase 1 clinical trial to evaluate the use of Codagenix's novel intranasal, live-attenuated virus vaccines, CoviLiv, as a booster in healthy adults following prior vaccination with approved COVID-19 vaccines.
- In May 2022, Jynneos, a live attenuated vaccines, is being developed by the European biotech firm Bavarian Nordic. The vaccines provides immunity against smallpox and monkeypox. In addition, the symptoms are mainly managed with antibiotics and hydration therapy.
- In May 2022, Valneva SE, a specialty vaccines company, announced the successful completion of the lot-to-lot Phase 3 trial of its single-shot chikungunya live attenuated vaccines candidate, VLA1553. The final analysis included six-month follow-up data and confirmed the topline results reported in December 2021.
- In July 2017, Emergent BioSolutions Inc., as authorized a concurrence with Valneva SE for worldwide selective rights to Valneva's Zika antibody innovation, ZIKV. This will assist the organization with procuring income creating items and advance items to line up with accomplices, for example, Valneva to foster inventive items that could serve the requirements of both government clients and the business market.
By Key Players
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Pfizer Inc.
- Sanofi
- Astellas Pharma
- Johnson & Johnson
- CSL Limited
- Serum Institute of India Pvt. Ltd.
Key Segments Covered in the Attenuated Vaccines Market Report
Attenuated Vaccines Market by Vaccines Type:
- Monovalent Attenuated Vaccines
- Multivalent Attenuated Vaccines
Attenuated Vaccines Market by Indication:
- Attenuated Vaccines for Influenza
- Attenuated Vaccines for Measles, Mumps & Rubella (MMR)
- Attenuated Vaccines for Polio
- Attenuated Vaccines for Chickenpox
- Attenuated Vaccines for Shingles
- Attenuated Vaccines for Rotavirus
- Attenuated Vaccines for Other Indications
Attenuated Vaccines Market by Route of Administration:
- Intramuscular Attenuated Vaccines Administration
- Subcutaneous Attenuated Vaccines Administration
- Oral Attenuated Vaccines Administration
- Intranasal Attenuated Vaccines Administration
- Intravenous Attenuated Vaccines Administration
Attenuated Vaccines Market by Age Group:
- Attenuated Vaccines for Pediatrics
- Attenuated Vaccines for Adolescents
- Attenuated Vaccines for Adults
- Attenuated Vaccines for Geriatric Patients
Attenuated Vaccines Market by End User:
- Attenuated Vaccines for Hospitals
- Attenuated Vaccines for Clinics
- Attenuated Vaccines for Other End Users
Attenuated Vaccines Market by Region:
- North America Attenuated Vaccines Market
- Latin America Attenuated Vaccines Market
- Europe Attenuated Vaccines Market
- East Asia Attenuated Vaccines Market
- South Asia Attenuated Vaccines Market
- Oceania Attenuated Vaccines Market
- Middle East & Africa Attenuated Vaccines Market
Frequently Asked Questions
According to Future Market Insights, the attenuated vaccines market was worth US$ 4,170.2 Million in 2021.
From 2012 to 2021, demand for attenuated vaccines surged at a 6.3% value CAGR.
From 2022-2032, the attenuated vaccines industry is poised to flourish at a CAGR of 6.8%.
As of 2022, the market for attenuated vaccines is poised to reach US$ 4,451.7 Million.
By 2032, sales of attenuated vaccines will likely be valued at US$ 9,305.8 Million, according to FMI.
Monovalent attenuated vaccines are expected to be most preferred, comprising over 70% of total deployment.
Attenuated vaccines for chickenpox will remain dominant, accounting for 38.1% of total market revenue.
According to FMI, North America is expected to document a 5.5% CAGR with regard to attenuated vaccines market growth.
South Asia is likely to be the most opportunistic market for attenuated vaccines in Asia, registering a 10.7% value CAGR.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Bn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Bn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Vaccine Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Bn) Analysis By Vaccine Type, 2017-2021
5.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Vaccine Type, 2022-2032
5.3.1. Monovalent Vaccines
5.3.2. Multivalent Vaccines
5.4. Y-o-Y Growth Trend Analysis By Vaccine Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Vaccine Type, 2022-2032
6. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Indication
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Bn) Analysis By Indication, 2017-2021
6.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Indication, 2022-2032
6.3.1. Influenza
6.3.2. Measles, Mumps & Rubella (MMR)
6.3.3. Polio
6.3.4. Chickenpox
6.3.5. Shingles
6.3.6. Rotavirus
6.3.7. Other Indications
6.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021
6.5. Absolute $ Opportunity Analysis By Indication, 2022-2032
7. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Bn) Analysis By Route of Administration, 2017-2021
7.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Route of Administration, 2022-2032
7.3.1. Intramuscular
7.3.2. Subcutaneous
7.3.3. Oral
7.3.4. Intranasal
7.3.5. Intravenous
7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021
7.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032
8. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Age Group
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Bn) Analysis By Age Group, 2017-2021
8.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Age Group, 2022-2032
8.3.1. Pediatric
8.3.2. Adolcents
8.3.3. Adults
8.3.4. Geriatric
8.4. Y-o-Y Growth Trend Analysis By Age Group, 2017-2021
8.5. Absolute $ Opportunity Analysis By Age Group, 2022-2032
9. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By End User
9.1. Introduction / Key Findings
9.2. Historical Market Size Value (US$ Bn) Analysis By End User, 2017-2021
9.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By End User, 2022-2032
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Others
9.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021
9.5. Absolute $ Opportunity Analysis By End User, 2022-2032
10. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Region
10.1. Introduction
10.2. Historical Market Size Value (US$ Bn) Analysis By Region, 2017-2021
10.3. Current Market Size Value (US$ Bn) Analysis and Forecast By Region, 2022-2032
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. East Asia
10.3.5. South Asia
10.3.6. Oceania
10.3.7. MEA
10.4. Market Attractiveness Analysis By Region
11. North America Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Value (US$ Bn)ed States
11.2.1.2. Canada
11.2.2. By Vaccine Type
11.2.3. By Indication
11.2.4. By Route of Administration
11.2.5. By Age Group
11.2.6. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Vaccine Type
11.3.3. By Indication
11.3.4. By Route of Administration
11.3.5. By Age Group
11.3.6. By End User
11.4. Key Takeaways
12. Latin America Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. Brazil
12.2.1.2. Mexico
12.2.1.3. Rest of Latin America
12.2.2. By Vaccine Type
12.2.3. By Indication
12.2.4. By Route of Administration
12.2.5. By Age Group
12.2.6. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Vaccine Type
12.3.3. By Indication
12.3.4. By Route of Administration
12.3.5. By Age Group
12.3.6. By End User
12.4. Key Takeaways
13. Europe Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. Germany
13.2.1.2. U.K.
13.2.1.3. France
13.2.1.4. Spain
13.2.1.5. Italy
13.2.1.6. Rest of Europe
13.2.2. By Vaccine Type
13.2.3. By Indication
13.2.4. By Route of Administration
13.2.5. By Age Group
13.2.6. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Vaccine Type
13.3.3. By Indication
13.3.4. By Route of Administration
13.3.5. By Age Group
13.3.6. By End User
13.4. Key Takeaways
14. East Asia Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Vaccine Type
14.2.3. By Indication
14.2.4. By Route of Administration
14.2.5. By Age Group
14.2.6. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Vaccine Type
14.3.3. By Indication
14.3.4. By Route of Administration
14.3.5. By Age Group
14.3.6. By End User
14.4. Key Takeaways
15. South Asia Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
15.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
15.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
15.2.1. By Country
15.2.1.1. India
15.2.1.2. ASEAN
15.2.1.3. Rest of South Asia
15.2.2. By Vaccine Type
15.2.3. By Indication
15.2.4. By Route of Administration
15.2.5. By Age Group
15.2.6. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Vaccine Type
15.3.3. By Indication
15.3.4. By Route of Administration
15.3.5. By Age Group
15.3.6. By End User
15.4. Key Takeaways
16. Oceania Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
16.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
16.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
16.2.1. By Country
16.2.1.1. Australia
16.2.1.2. New Zealand
16.2.2. By Vaccine Type
16.2.3. By Indication
16.2.4. By Route of Administration
16.2.5. By Age Group
16.2.6. By End User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Vaccine Type
16.3.3. By Indication
16.3.4. By Route of Administration
16.3.5. By Age Group
16.3.6. By End User
16.4. Key Takeaways
17. MEA Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
17.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
17.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
17.2.1. By Country
17.2.1.1. GCC Countries
17.2.1.2. South Africa
17.2.1.3. Israel
17.2.1.4. Rest of MEA
17.2.2. By Vaccine Type
17.2.3. By Indication
17.2.4. By Route of Administration
17.2.5. By Age Group
17.2.6. By End User
17.3. Market Attractiveness Analysis
17.3.1. By Country
17.3.2. By Vaccine Type
17.3.3. By Indication
17.3.4. By Route of Administration
17.3.5. By Age Group
17.3.6. By End User
17.4. Key Takeaways
18. Key Countries Attenuated Vaccines Market Analysis
18.1. Value (US$ Bn)ed States
18.1.1. Pricing Analysis
18.1.2. Market Share Analysis, 2021
18.1.2.1. By Vaccine Type
18.1.2.2. By Indication
18.1.2.3. By Route of Administration
18.1.2.4. By Age Group
18.1.2.5. By End User
18.2. Canada
18.2.1. Pricing Analysis
18.2.2. Market Share Analysis, 2021
18.2.2.1. By Vaccine Type
18.2.2.2. By Indication
18.2.2.3. By Route of Administration
18.2.2.4. By Age Group
18.2.2.5. By End User
18.3. Brazil
18.3.1. Pricing Analysis
18.3.2. Market Share Analysis, 2021
18.3.2.1. By Vaccine Type
18.3.2.2. By Indication
18.3.2.3. By Route of Administration
18.3.2.4. By Age Group
18.3.2.5. By End User
18.4. Mexico
18.4.1. Pricing Analysis
18.4.2. Market Share Analysis, 2021
18.4.2.1. By Vaccine Type
18.4.2.2. By Indication
18.4.2.3. By Route of Administration
18.4.2.4. By Age Group
18.4.2.5. By End User
18.5. Rest of Latin America
18.5.1. Pricing Analysis
18.5.2. Market Share Analysis, 2021
18.5.2.1. By Vaccine Type
18.5.2.2. By Indication
18.5.2.3. By Route of Administration
18.5.2.4. By Age Group
18.5.2.5. By End User
18.6. Germany
18.6.1. Pricing Analysis
18.6.2. Market Share Analysis, 2021
18.6.2.1. By Vaccine Type
18.6.2.2. By Indication
18.6.2.3. By Route of Administration
18.6.2.4. By Age Group
18.6.2.5. By End User
18.7. U.K.
18.7.1. Pricing Analysis
18.7.2. Market Share Analysis, 2021
18.7.2.1. By Vaccine Type
18.7.2.2. By Indication
18.7.2.3. By Route of Administration
18.7.2.4. By Age Group
18.7.2.5. By End User
18.8. France
18.8.1. Pricing Analysis
18.8.2. Market Share Analysis, 2021
18.8.2.1. By Vaccine Type
18.8.2.2. By Indication
18.8.2.3. By Route of Administration
18.8.2.4. By Age Group
18.8.2.5. By End User
18.9. Spain
18.9.1. Pricing Analysis
18.9.2. Market Share Analysis, 2021
18.9.2.1. By Vaccine Type
18.9.2.2. By Indication
18.9.2.3. By Route of Administration
18.9.2.4. By Age Group
18.9.2.5. By End User
18.10. Italy
18.10.1. Pricing Analysis
18.10.2. Market Share Analysis, 2021
18.10.2.1. By Vaccine Type
18.10.2.2. By Indication
18.10.2.3. By Route of Administration
18.10.2.4. By Age Group
18.10.2.5. By End User
18.11. Rest of Europe
18.11.1. Pricing Analysis
18.11.2. Market Share Analysis, 2021
18.11.2.1. By Vaccine Type
18.11.2.2. By Indication
18.11.2.3. By Route of Administration
18.11.2.4. By Age Group
18.11.2.5. By End User
18.12. China
18.12.1. Pricing Analysis
18.12.2. Market Share Analysis, 2021
18.12.2.1. By Vaccine Type
18.12.2.2. By Indication
18.12.2.3. By Route of Administration
18.12.2.4. By Age Group
18.12.2.5. By End User
18.13. Japan
18.13.1. Pricing Analysis
18.13.2. Market Share Analysis, 2021
18.13.2.1. By Vaccine Type
18.13.2.2. By Indication
18.13.2.3. By Route of Administration
18.13.2.4. By Age Group
18.13.2.5. By End User
18.14. South Korea
18.14.1. Pricing Analysis
18.14.2. Market Share Analysis, 2021
18.14.2.1. By Vaccine Type
18.14.2.2. By Indication
18.14.2.3. By Route of Administration
18.14.2.4. By Age Group
18.14.2.5. By End User
18.15. India
18.15.1. Pricing Analysis
18.15.2. Market Share Analysis, 2021
18.15.2.1. By Vaccine Type
18.15.2.2. By Indication
18.15.2.3. By Route of Administration
18.15.2.4. By Age Group
18.15.2.5. By End User
18.16. ASEAN
18.16.1. Pricing Analysis
18.16.2. Market Share Analysis, 2021
18.16.2.1. By Vaccine Type
18.16.2.2. By Indication
18.16.2.3. By Route of Administration
18.16.2.4. By Age Group
18.16.2.5. By End User
18.17. Rest of South Asia
18.17.1. Pricing Analysis
18.17.2. Market Share Analysis, 2021
18.17.2.1. By Vaccine Type
18.17.2.2. By Indication
18.17.2.3. By Route of Administration
18.17.2.4. By Age Group
18.17.2.5. By End User
18.18. Australia
18.18.1. Pricing Analysis
18.18.2. Market Share Analysis, 2021
18.18.2.1. By Vaccine Type
18.18.2.2. By Indication
18.18.2.3. By Route of Administration
18.18.2.4. By Age Group
18.18.2.5. By End User
18.19. New Zealand
18.19.1. Pricing Analysis
18.19.2. Market Share Analysis, 2021
18.19.2.1. By Vaccine Type
18.19.2.2. By Indication
18.19.2.3. By Route of Administration
18.19.2.4. By Age Group
18.19.2.5. By End User
18.20. GCC Countries
18.20.1. Pricing Analysis
18.20.2. Market Share Analysis, 2021
18.20.2.1. By Vaccine Type
18.20.2.2. By Indication
18.20.2.3. By Route of Administration
18.20.2.4. By Age Group
18.20.2.5. By End User
18.21. South Africa
18.21.1. Pricing Analysis
18.21.2. Market Share Analysis, 2021
18.21.2.1. By Vaccine Type
18.21.2.2. By Indication
18.21.2.3. By Route of Administration
18.21.2.4. By Age Group
18.21.2.5. By End User
18.22. Israel
18.22.1. Pricing Analysis
18.22.2. Market Share Analysis, 2021
18.22.2.1. By Vaccine Type
18.22.2.2. By Indication
18.22.2.3. By Route of Administration
18.22.2.4. By Age Group
18.22.2.5. By End User
18.23. Rest of MEA
18.23.1. Pricing Analysis
18.23.2. Market Share Analysis, 2021
18.23.2.1. By Vaccine Type
18.23.2.2. By Indication
18.23.2.3. By Route of Administration
18.23.2.4. By Age Group
18.23.2.5. By End User
19. Market Structure Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Market Share Analysis of Top Players
19.3.1. By Regional
19.3.2. By Vaccine Type
19.3.3. By Indication
19.3.4. By Route of Administration
19.3.5. By Age Group
19.3.6. By End User
20. Competition Analysis
20.1. Competition Deep Dive
20.1.1. GlaxoSmithKline
20.1.1.1. Overview
20.1.1.2. Product Portfolio
20.1.1.3. Profitability by Market Segments
20.1.1.4. Sales Footprint
20.1.1.5. Strategy Overview
20.1.1.5.1. Marketing Strategy
20.1.2. Merck
20.1.2.1. Overview
20.1.2.2. Product Portfolio
20.1.2.3. Profitability by Market Segments
20.1.2.4. Sales Footprint
20.1.2.5. Strategy Overview
20.1.2.5.1. Marketing Strategy
20.1.3. Pfizer
20.1.3.1. Overview
20.1.3.2. Product Portfolio
20.1.3.3. Profitability by Market Segments
20.1.3.4. Sales Footprint
20.1.3.5. Strategy Overview
20.1.3.5.1. Marketing Strategy
20.1.4. Sanofi
20.1.4.1. Overview
20.1.4.2. Product Portfolio
20.1.4.3. Profitability by Market Segments
20.1.4.4. Sales Footprint
20.1.4.5. Strategy Overview
20.1.4.5.1. Marketing Strategy
20.1.5. Astellas Pharma
20.1.5.1. Overview
20.1.5.2. Product Portfolio
20.1.5.3. Profitability by Market Segments
20.1.5.4. Sales Footprint
20.1.5.5. Strategy Overview
20.1.5.5.1. Marketing Strategy
20.1.6. Johnson and Johnson
20.1.6.1. Overview
20.1.6.2. Product Portfolio
20.1.6.3. Profitability by Market Segments
20.1.6.4. Sales Footprint
20.1.6.5. Strategy Overview
20.1.6.5.1. Marketing Strategy
20.1.7. CSL
20.1.7.1. Overview
20.1.7.2. Product Portfolio
20.1.7.3. Profitability by Market Segments
20.1.7.4. Sales Footprint
20.1.7.5. Strategy Overview
20.1.7.5.1. Marketing Strategy
20.1.8. Serum Institute Of India
20.1.8.1. Overview
20.1.8.2. Product Portfolio
20.1.8.3. Profitability by Market Segments
20.1.8.4. Sales Footprint
20.1.8.5. Strategy Overview
20.1.8.5.1. Marketing Strategy
21. Assumptions & Acronyms Used
22. Research Methodology
Let us know your requirement to get
100% FREE customization
Table 1: Global Attenuated Vaccines Market Value (US$ Bn) Forecast by Region, 2017-2032
Table 2: Global Attenuated Vaccines Market Value (US$ Bn) Forecast by Vaccine Type, 2017-2032
Table 3: Global Attenuated Vaccines Market Value (US$ Bn) Forecast by Indication, 2017-2032
Table 4: Global Attenuated Vaccines Market Value (US$ Bn) Forecast by Route of Administration, 2017-2032
Table 5: Global Attenuated Vaccines Market Value (US$ Bn) Forecast by Age Group, 2017-2032
Table 6: Global Attenuated Vaccines Market Value (US$ Bn) Forecast by End User, 2017-2032
Table 7: North America Attenuated Vaccines Market Value (US$ Bn) Forecast by Country, 2017-2032
Table 8: North America Attenuated Vaccines Market Value (US$ Bn) Forecast by Vaccine Type, 2017-2032
Table 9: North America Attenuated Vaccines Market Value (US$ Bn) Forecast by Indication, 2017-2032
Table 10: North America Attenuated Vaccines Market Value (US$ Bn) Forecast by Route of Administration, 2017-2032
Table 11: North America Attenuated Vaccines Market Value (US$ Bn) Forecast by Age Group, 2017-2032
Table 12: North America Attenuated Vaccines Market Value (US$ Bn) Forecast by End User, 2017-2032
Table 13: Latin America Attenuated Vaccines Market Value (US$ Bn) Forecast by Country, 2017-2032
Table 14: Latin America Attenuated Vaccines Market Value (US$ Bn) Forecast by Vaccine Type, 2017-2032
Table 15: Latin America Attenuated Vaccines Market Value (US$ Bn) Forecast by Indication, 2017-2032
Table 16: Latin America Attenuated Vaccines Market Value (US$ Bn) Forecast by Route of Administration, 2017-2032
Table 17: Latin America Attenuated Vaccines Market Value (US$ Bn) Forecast by Age Group, 2017-2032
Table 18: Latin America Attenuated Vaccines Market Value (US$ Bn) Forecast by End User, 2017-2032
Table 19: Europe Attenuated Vaccines Market Value (US$ Bn) Forecast by Country, 2017-2032
Table 20: Europe Attenuated Vaccines Market Value (US$ Bn) Forecast by Vaccine Type, 2017-2032
Table 21: Europe Attenuated Vaccines Market Value (US$ Bn) Forecast by Indication, 2017-2032
Table 22: Europe Attenuated Vaccines Market Value (US$ Bn) Forecast by Route of Administration, 2017-2032
Table 23: Europe Attenuated Vaccines Market Value (US$ Bn) Forecast by Age Group, 2017-2032
Table 24: Europe Attenuated Vaccines Market Value (US$ Bn) Forecast by End User, 2017-2032
Table 25: East Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Country, 2017-2032
Table 26: East Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Vaccine Type, 2017-2032
Table 27: East Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Indication, 2017-2032
Table 28: East Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Route of Administration, 2017-2032
Table 29: East Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Age Group, 2017-2032
Table 30: East Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by End User, 2017-2032
Table 31: South Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Country, 2017-2032
Table 32: South Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Vaccine Type, 2017-2032
Table 33: South Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Indication, 2017-2032
Table 34: South Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Route of Administration, 2017-2032
Table 35: South Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by Age Group, 2017-2032
Table 36: South Asia Attenuated Vaccines Market Value (US$ Bn) Forecast by End User, 2017-2032
Table 37: Oceania Attenuated Vaccines Market Value (US$ Bn) Forecast by Country, 2017-2032
Table 38: Oceania Attenuated Vaccines Market Value (US$ Bn) Forecast by Vaccine Type, 2017-2032
Table 39: Oceania Attenuated Vaccines Market Value (US$ Bn) Forecast by Indication, 2017-2032
Table 40: Oceania Attenuated Vaccines Market Value (US$ Bn) Forecast by Route of Administration, 2017-2032
Table 41: Oceania Attenuated Vaccines Market Value (US$ Bn) Forecast by Age Group, 2017-2032
Table 42: Oceania Attenuated Vaccines Market Value (US$ Bn) Forecast by End User, 2017-2032
Table 43: MEA Attenuated Vaccines Market Value (US$ Bn) Forecast by Country, 2017-2032
Table 44: MEA Attenuated Vaccines Market Value (US$ Bn) Forecast by Vaccine Type, 2017-2032
Table 45: MEA Attenuated Vaccines Market Value (US$ Bn) Forecast by Indication, 2017-2032
Table 46: MEA Attenuated Vaccines Market Value (US$ Bn) Forecast by Route of Administration, 2017-2032
Table 47: MEA Attenuated Vaccines Market Value (US$ Bn) Forecast by Age Group, 2017-2032
Table 48: MEA Attenuated Vaccines Market Value (US$ Bn) Forecast by End User, 2017-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystFigure 1: Global Attenuated Vaccines Market Value (US$ Bn) by Vaccine Type, 2022-2032
Figure 2: Global Attenuated Vaccines Market Value (US$ Bn) by Indication, 2022-2032
Figure 3: Global Attenuated Vaccines Market Value (US$ Bn) by Route of Administration, 2022-2032
Figure 4: Global Attenuated Vaccines Market Value (US$ Bn) by Age Group, 2022-2032
Figure 5: Global Attenuated Vaccines Market Value (US$ Bn) by End User, 2022-2032
Figure 6: Global Attenuated Vaccines Market Value (US$ Bn) by Region, 2022-2032
Figure 7: Global Attenuated Vaccines Market Value (US$ Bn) Analysis by Region, 2017-2032
Figure 8: Global Attenuated Vaccines Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 9: Global Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 10: Global Attenuated Vaccines Market Value (US$ Bn) Analysis by Vaccine Type, 2017-2032
Figure 11: Global Attenuated Vaccines Market Value Share (%) and BPS Analysis by Vaccine Type, 2022-2032
Figure 12: Global Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Vaccine Type, 2022-2032
Figure 13: Global Attenuated Vaccines Market Value (US$ Bn) Analysis by Indication, 2017-2032
Figure 14: Global Attenuated Vaccines Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 15: Global Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 16: Global Attenuated Vaccines Market Value (US$ Bn) Analysis by Route of Administration, 2017-2032
Figure 17: Global Attenuated Vaccines Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 18: Global Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 19: Global Attenuated Vaccines Market Value (US$ Bn) Analysis by Age Group, 2017-2032
Figure 20: Global Attenuated Vaccines Market Value Share (%) and BPS Analysis by Age Group, 2022-2032
Figure 21: Global Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Age Group, 2022-2032
Figure 22: Global Attenuated Vaccines Market Value (US$ Bn) Analysis by End User, 2017-2032
Figure 23: Global Attenuated Vaccines Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 24: Global Attenuated Vaccines Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 25: Global Attenuated Vaccines Market Attractiveness by Vaccine Type, 2022-2032
Figure 26: Global Attenuated Vaccines Market Attractiveness by Indication, 2022-2032
Figure 27: Global Attenuated Vaccines Market Attractiveness by Route of Administration, 2022-2032
Figure 28: Global Attenuated Vaccines Market Attractiveness by Age Group, 2022-2032
Figure 29: Global Attenuated Vaccines Market Attractiveness by End User, 2022-2032
Figure 30: Global Attenuated Vaccines Market Attractiveness by Region, 2022-2032
Figure 31: North America Attenuated Vaccines Market Value (US$ Bn) by Vaccine Type, 2022-2032
Figure 32: North America Attenuated Vaccines Market Value (US$ Bn) by Indication, 2022-2032
Figure 33: North America Attenuated Vaccines Market Value (US$ Bn) by Route of Administration, 2022-2032
Figure 34: North America Attenuated Vaccines Market Value (US$ Bn) by Age Group, 2022-2032
Figure 35: North America Attenuated Vaccines Market Value (US$ Bn) by End User, 2022-2032
Figure 36: North America Attenuated Vaccines Market Value (US$ Bn) by Country, 2022-2032
Figure 37: North America Attenuated Vaccines Market Value (US$ Bn) Analysis by Country, 2017-2032
Figure 38: North America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 39: North America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 40: North America Attenuated Vaccines Market Value (US$ Bn) Analysis by Vaccine Type, 2017-2032
Figure 41: North America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Vaccine Type, 2022-2032
Figure 42: North America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Vaccine Type, 2022-2032
Figure 43: North America Attenuated Vaccines Market Value (US$ Bn) Analysis by Indication, 2017-2032
Figure 44: North America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 45: North America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 46: North America Attenuated Vaccines Market Value (US$ Bn) Analysis by Route of Administration, 2017-2032
Figure 47: North America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 48: North America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 49: North America Attenuated Vaccines Market Value (US$ Bn) Analysis by Age Group, 2017-2032
Figure 50: North America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Age Group, 2022-2032
Figure 51: North America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Age Group, 2022-2032
Figure 52: North America Attenuated Vaccines Market Value (US$ Bn) Analysis by End User, 2017-2032
Figure 53: North America Attenuated Vaccines Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 54: North America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 55: North America Attenuated Vaccines Market Attractiveness by Vaccine Type, 2022-2032
Figure 56: North America Attenuated Vaccines Market Attractiveness by Indication, 2022-2032
Figure 57: North America Attenuated Vaccines Market Attractiveness by Route of Administration, 2022-2032
Figure 58: North America Attenuated Vaccines Market Attractiveness by Age Group, 2022-2032
Figure 59: North America Attenuated Vaccines Market Attractiveness by End User, 2022-2032
Figure 60: North America Attenuated Vaccines Market Attractiveness by Country, 2022-2032
Figure 61: Latin America Attenuated Vaccines Market Value (US$ Bn) by Vaccine Type, 2022-2032
Figure 62: Latin America Attenuated Vaccines Market Value (US$ Bn) by Indication, 2022-2032
Figure 63: Latin America Attenuated Vaccines Market Value (US$ Bn) by Route of Administration, 2022-2032
Figure 64: Latin America Attenuated Vaccines Market Value (US$ Bn) by Age Group, 2022-2032
Figure 65: Latin America Attenuated Vaccines Market Value (US$ Bn) by End User, 2022-2032
Figure 66: Latin America Attenuated Vaccines Market Value (US$ Bn) by Country, 2022-2032
Figure 67: Latin America Attenuated Vaccines Market Value (US$ Bn) Analysis by Country, 2017-2032
Figure 68: Latin America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 69: Latin America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 70: Latin America Attenuated Vaccines Market Value (US$ Bn) Analysis by Vaccine Type, 2017-2032
Figure 71: Latin America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Vaccine Type, 2022-2032
Figure 72: Latin America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Vaccine Type, 2022-2032
Figure 73: Latin America Attenuated Vaccines Market Value (US$ Bn) Analysis by Indication, 2017-2032
Figure 74: Latin America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 75: Latin America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 76: Latin America Attenuated Vaccines Market Value (US$ Bn) Analysis by Route of Administration, 2017-2032
Figure 77: Latin America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 78: Latin America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 79: Latin America Attenuated Vaccines Market Value (US$ Bn) Analysis by Age Group, 2017-2032
Figure 80: Latin America Attenuated Vaccines Market Value Share (%) and BPS Analysis by Age Group, 2022-2032
Figure 81: Latin America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Age Group, 2022-2032
Figure 82: Latin America Attenuated Vaccines Market Value (US$ Bn) Analysis by End User, 2017-2032
Figure 83: Latin America Attenuated Vaccines Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 84: Latin America Attenuated Vaccines Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 85: Latin America Attenuated Vaccines Market Attractiveness by Vaccine Type, 2022-2032
Figure 86: Latin America Attenuated Vaccines Market Attractiveness by Indication, 2022-2032
Figure 87: Latin America Attenuated Vaccines Market Attractiveness by Route of Administration, 2022-2032
Figure 88: Latin America Attenuated Vaccines Market Attractiveness by Age Group, 2022-2032
Figure 89: Latin America Attenuated Vaccines Market Attractiveness by End User, 2022-2032
Figure 90: Latin America Attenuated Vaccines Market Attractiveness by Country, 2022-2032
Figure 91: Europe Attenuated Vaccines Market Value (US$ Bn) by Vaccine Type, 2022-2032
Figure 92: Europe Attenuated Vaccines Market Value (US$ Bn) by Indication, 2022-2032
Figure 93: Europe Attenuated Vaccines Market Value (US$ Bn) by Route of Administration, 2022-2032
Figure 94: Europe Attenuated Vaccines Market Value (US$ Bn) by Age Group, 2022-2032
Figure 95: Europe Attenuated Vaccines Market Value (US$ Bn) by End User, 2022-2032
Figure 96: Europe Attenuated Vaccines Market Value (US$ Bn) by Country, 2022-2032
Figure 97: Europe Attenuated Vaccines Market Value (US$ Bn) Analysis by Country, 2017-2032
Figure 98: Europe Attenuated Vaccines Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 99: Europe Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 100: Europe Attenuated Vaccines Market Value (US$ Bn) Analysis by Vaccine Type, 2017-2032
Figure 101: Europe Attenuated Vaccines Market Value Share (%) and BPS Analysis by Vaccine Type, 2022-2032
Figure 102: Europe Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Vaccine Type, 2022-2032
Figure 103: Europe Attenuated Vaccines Market Value (US$ Bn) Analysis by Indication, 2017-2032
Figure 104: Europe Attenuated Vaccines Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 105: Europe Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 106: Europe Attenuated Vaccines Market Value (US$ Bn) Analysis by Route of Administration, 2017-2032
Figure 107: Europe Attenuated Vaccines Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 108: Europe Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 109: Europe Attenuated Vaccines Market Value (US$ Bn) Analysis by Age Group, 2017-2032
Figure 110: Europe Attenuated Vaccines Market Value Share (%) and BPS Analysis by Age Group, 2022-2032
Figure 111: Europe Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Age Group, 2022-2032
Figure 112: Europe Attenuated Vaccines Market Value (US$ Bn) Analysis by End User, 2017-2032
Figure 113: Europe Attenuated Vaccines Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 114: Europe Attenuated Vaccines Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 115: Europe Attenuated Vaccines Market Attractiveness by Vaccine Type, 2022-2032
Figure 116: Europe Attenuated Vaccines Market Attractiveness by Indication, 2022-2032
Figure 117: Europe Attenuated Vaccines Market Attractiveness by Route of Administration, 2022-2032
Figure 118: Europe Attenuated Vaccines Market Attractiveness by Age Group, 2022-2032
Figure 119: Europe Attenuated Vaccines Market Attractiveness by End User, 2022-2032
Figure 120: Europe Attenuated Vaccines Market Attractiveness by Country, 2022-2032
Figure 121: East Asia Attenuated Vaccines Market Value (US$ Bn) by Vaccine Type, 2022-2032
Figure 122: East Asia Attenuated Vaccines Market Value (US$ Bn) by Indication, 2022-2032
Figure 123: East Asia Attenuated Vaccines Market Value (US$ Bn) by Route of Administration, 2022-2032
Figure 124: East Asia Attenuated Vaccines Market Value (US$ Bn) by Age Group, 2022-2032
Figure 125: East Asia Attenuated Vaccines Market Value (US$ Bn) by End User, 2022-2032
Figure 126: East Asia Attenuated Vaccines Market Value (US$ Bn) by Country, 2022-2032
Figure 127: East Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Country, 2017-2032
Figure 128: East Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 129: East Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 130: East Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Vaccine Type, 2017-2032
Figure 131: East Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Vaccine Type, 2022-2032
Figure 132: East Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Vaccine Type, 2022-2032
Figure 133: East Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Indication, 2017-2032
Figure 134: East Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 135: East Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 136: East Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Route of Administration, 2017-2032
Figure 137: East Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 138: East Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 139: East Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Age Group, 2017-2032
Figure 140: East Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Age Group, 2022-2032
Figure 141: East Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Age Group, 2022-2032
Figure 142: East Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by End User, 2017-2032
Figure 143: East Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 144: East Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 145: East Asia Attenuated Vaccines Market Attractiveness by Vaccine Type, 2022-2032
Figure 146: East Asia Attenuated Vaccines Market Attractiveness by Indication, 2022-2032
Figure 147: East Asia Attenuated Vaccines Market Attractiveness by Route of Administration, 2022-2032
Figure 148: East Asia Attenuated Vaccines Market Attractiveness by Age Group, 2022-2032
Figure 149: East Asia Attenuated Vaccines Market Attractiveness by End User, 2022-2032
Figure 150: East Asia Attenuated Vaccines Market Attractiveness by Country, 2022-2032
Figure 151: South Asia Attenuated Vaccines Market Value (US$ Bn) by Vaccine Type, 2022-2032
Figure 152: South Asia Attenuated Vaccines Market Value (US$ Bn) by Indication, 2022-2032
Figure 153: South Asia Attenuated Vaccines Market Value (US$ Bn) by Route of Administration, 2022-2032
Figure 154: South Asia Attenuated Vaccines Market Value (US$ Bn) by Age Group, 2022-2032
Figure 155: South Asia Attenuated Vaccines Market Value (US$ Bn) by End User, 2022-2032
Figure 156: South Asia Attenuated Vaccines Market Value (US$ Bn) by Country, 2022-2032
Figure 157: South Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Country, 2017-2032
Figure 158: South Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 159: South Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 160: South Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Vaccine Type, 2017-2032
Figure 161: South Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Vaccine Type, 2022-2032
Figure 162: South Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Vaccine Type, 2022-2032
Figure 163: South Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Indication, 2017-2032
Figure 164: South Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 165: South Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 166: South Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Route of Administration, 2017-2032
Figure 167: South Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 168: South Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 169: South Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by Age Group, 2017-2032
Figure 170: South Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by Age Group, 2022-2032
Figure 171: South Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Age Group, 2022-2032
Figure 172: South Asia Attenuated Vaccines Market Value (US$ Bn) Analysis by End User, 2017-2032
Figure 173: South Asia Attenuated Vaccines Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 174: South Asia Attenuated Vaccines Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 175: South Asia Attenuated Vaccines Market Attractiveness by Vaccine Type, 2022-2032
Figure 176: South Asia Attenuated Vaccines Market Attractiveness by Indication, 2022-2032
Figure 177: South Asia Attenuated Vaccines Market Attractiveness by Route of Administration, 2022-2032
Figure 178: South Asia Attenuated Vaccines Market Attractiveness by Age Group, 2022-2032
Figure 179: South Asia Attenuated Vaccines Market Attractiveness by End User, 2022-2032
Figure 180: South Asia Attenuated Vaccines Market Attractiveness by Country, 2022-2032
Figure 181: Oceania Attenuated Vaccines Market Value (US$ Bn) by Vaccine Type, 2022-2032
Figure 182: Oceania Attenuated Vaccines Market Value (US$ Bn) by Indication, 2022-2032
Figure 183: Oceania Attenuated Vaccines Market Value (US$ Bn) by Route of Administration, 2022-2032
Figure 184: Oceania Attenuated Vaccines Market Value (US$ Bn) by Age Group, 2022-2032
Figure 185: Oceania Attenuated Vaccines Market Value (US$ Bn) by End User, 2022-2032
Figure 186: Oceania Attenuated Vaccines Market Value (US$ Bn) by Country, 2022-2032
Figure 187: Oceania Attenuated Vaccines Market Value (US$ Bn) Analysis by Country, 2017-2032
Figure 188: Oceania Attenuated Vaccines Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 189: Oceania Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 190: Oceania Attenuated Vaccines Market Value (US$ Bn) Analysis by Vaccine Type, 2017-2032
Figure 191: Oceania Attenuated Vaccines Market Value Share (%) and BPS Analysis by Vaccine Type, 2022-2032
Figure 192: Oceania Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Vaccine Type, 2022-2032
Figure 193: Oceania Attenuated Vaccines Market Value (US$ Bn) Analysis by Indication, 2017-2032
Figure 194: Oceania Attenuated Vaccines Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 195: Oceania Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 196: Oceania Attenuated Vaccines Market Value (US$ Bn) Analysis by Route of Administration, 2017-2032
Figure 197: Oceania Attenuated Vaccines Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 198: Oceania Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 199: Oceania Attenuated Vaccines Market Value (US$ Bn) Analysis by Age Group, 2017-2032
Figure 200: Oceania Attenuated Vaccines Market Value Share (%) and BPS Analysis by Age Group, 2022-2032
Figure 201: Oceania Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Age Group, 2022-2032
Figure 202: Oceania Attenuated Vaccines Market Value (US$ Bn) Analysis by End User, 2017-2032
Figure 203: Oceania Attenuated Vaccines Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 204: Oceania Attenuated Vaccines Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 205: Oceania Attenuated Vaccines Market Attractiveness by Vaccine Type, 2022-2032
Figure 206: Oceania Attenuated Vaccines Market Attractiveness by Indication, 2022-2032
Figure 207: Oceania Attenuated Vaccines Market Attractiveness by Route of Administration, 2022-2032
Figure 208: Oceania Attenuated Vaccines Market Attractiveness by Age Group, 2022-2032
Figure 209: Oceania Attenuated Vaccines Market Attractiveness by End User, 2022-2032
Figure 210: Oceania Attenuated Vaccines Market Attractiveness by Country, 2022-2032
Figure 211: MEA Attenuated Vaccines Market Value (US$ Bn) by Vaccine Type, 2022-2032
Figure 212: MEA Attenuated Vaccines Market Value (US$ Bn) by Indication, 2022-2032
Figure 213: MEA Attenuated Vaccines Market Value (US$ Bn) by Route of Administration, 2022-2032
Figure 214: MEA Attenuated Vaccines Market Value (US$ Bn) by Age Group, 2022-2032
Figure 215: MEA Attenuated Vaccines Market Value (US$ Bn) by End User, 2022-2032
Figure 216: MEA Attenuated Vaccines Market Value (US$ Bn) by Country, 2022-2032
Figure 217: MEA Attenuated Vaccines Market Value (US$ Bn) Analysis by Country, 2017-2032
Figure 218: MEA Attenuated Vaccines Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 219: MEA Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 220: MEA Attenuated Vaccines Market Value (US$ Bn) Analysis by Vaccine Type, 2017-2032
Figure 221: MEA Attenuated Vaccines Market Value Share (%) and BPS Analysis by Vaccine Type, 2022-2032
Figure 222: MEA Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Vaccine Type, 2022-2032
Figure 223: MEA Attenuated Vaccines Market Value (US$ Bn) Analysis by Indication, 2017-2032
Figure 224: MEA Attenuated Vaccines Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 225: MEA Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 226: MEA Attenuated Vaccines Market Value (US$ Bn) Analysis by Route of Administration, 2017-2032
Figure 227: MEA Attenuated Vaccines Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 228: MEA Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 229: MEA Attenuated Vaccines Market Value (US$ Bn) Analysis by Age Group, 2017-2032
Figure 230: MEA Attenuated Vaccines Market Value Share (%) and BPS Analysis by Age Group, 2022-2032
Figure 231: MEA Attenuated Vaccines Market Y-o-Y Growth (%) Projections by Age Group, 2022-2032
Figure 232: MEA Attenuated Vaccines Market Value (US$ Bn) Analysis by End User, 2017-2032
Figure 233: MEA Attenuated Vaccines Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 234: MEA Attenuated Vaccines Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 235: MEA Attenuated Vaccines Market Attractiveness by Vaccine Type, 2022-2032
Figure 236: MEA Attenuated Vaccines Market Attractiveness by Indication, 2022-2032
Figure 237: MEA Attenuated Vaccines Market Attractiveness by Route of Administration, 2022-2032
Figure 238: MEA Attenuated Vaccines Market Attractiveness by Age Group, 2022-2032
Figure 239: MEA Attenuated Vaccines Market Attractiveness by End User, 2022-2032
Figure 240: MEA Attenuated Vaccines Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
